Fundraising FoxDialectic Therapeutics
San Antonio, US · Founded 2018 · Delaware corporation
Find your way into Dialectic Therapeutics
Sign up to find every way you can get introduced to Dialectic Therapeutics
- Your email: who you already know at Dialectic Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Dialectic Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Dialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Founders & leadership
Dialectic Therapeutics was founded in 2018 by Daohong Zhou, Guangrong Zheng, and John D. Harkey Jr., JD, MBA.
Funding
SEC filings, press & company announcements$8.8M disclosed across 3 of 4 rounds · 2018–2020
- Undisclosed amountSeedFeb 2020Source ↗
▶$6.3MraisedFeb 2021 · 27 investors · BiotechnologyRule 506(b)
- David GenecovExecutive Officer, Director
- John D. HarkeyDirector
- Daohong ZhouDirector
- Joshua SillsExecutive Officer
- Robert HromasDirector
- Offering amount
- $6.3M
- Amount sold
- $6.3M
- Minimum investment
- $50K
- Proceeds to insiders
- $100K
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$500KraisedOct 2020 · 12 investors · BiotechnologyRule 506(b)
- John D. HarkeyDirector
- David GenecovExecutive Officer, Director
- Daohong ZhouDirector
- Robert HromasDirector
- Offering amount
- $500K
- Amount sold
- $500K
- Minimum investment
- $2.5K
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$2MraisedNov 2018 · 2 investors · BiotechnologyRule 506(b)
- David GenecovDirector
- John D. HarkeyDirector
- Daohong ZhouExecutive Officer, Director
- Robert HromasExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $2M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Dialectic Therapeutics.
In the news
Frequently asked questions
- What does Dialectic Therapeutics do?
- Dialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
- Who founded Dialectic Therapeutics?
- Dialectic Therapeutics was founded by Daohong Zhou, Guangrong Zheng, John D. Harkey Jr., JD, MBA in 2018.
- How much funding has Dialectic Therapeutics raised?
- Dialectic Therapeutics has disclosed $8.8M raised across 3 of its 4 known rounds.
- Where is Dialectic Therapeutics headquartered?
- Dialectic Therapeutics is headquartered in San Antonio, US.